ADELIS Technologies

🎉L'équipe Adelis s'agrandit avec de nouveaux talents !🎉 Nous sommes ravis d'accueillir trois collaborateurs qui viennent renforcer notre équipe : 👉 Lucas Malpartida – Responsable Développement Produits (à gauche sur la photo) 👉 Ramzi BOUSADIA – Ingénieur Informatique Embarquée (à droite) 👉 Guillaume Bourges – Responsable Développement Logiciels Leur expertise sera un atout pour nos projets à venir. #Welcome #TeamAdelis #Innovation #Développement

The Liquid Biopsy Market focuses on a non-invasive diagnostic technique that analyzes circulating biomarkers in bodily fluids (usually blood) to detect and monitor diseases, particularly cancer. Liquid biopsies are increasingly used for early cancer detection, treatment monitoring, and personalized medicine. Global Liquid Biopsy Market size was valued at USD 2.12 Billion in 2021 and is projected to reach USD 6.54 Billion by 2028, growing at a CAGR of 20.84% from 2021 to 2028 according to a new report by Intellectual Market Insights Research. IMIR Market Research Pvt. Ltd. 𝐆𝐞𝐭 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dgUidUC3 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭: Ikonisys RealSeq Biosciences Fraunhofer IMM NVIGEN Inc. HUMINN Tethis S.p.A SmartCatch GC Genome EDGC(EONE-DIAGNOMICS Genome Center) Noscendo GmbH Clearbridge Health Limited AccuraGen GENECAST PrecisionMed Apostle Inc Redbud Labs Cordance Medical Cancer Research UK National Biomarker Centre Geninus Inc. CTOAM | Cancer Treatment Options & Management METHYS Dx Zinexts Life Science Corp. DeltaBio Genece Health Telo Genomics Senseera Clinomics   Yourgene Health Canada GeneCast Biotechnology Co., Ltd. HLB PANAGENE Co., LTD. IMBdx MetaSight Diagnostics HaploX Biotechnology QCDx   IMSTAR Dx ResourcePath Cellomics International Limited ADELIS Technologies MiCareo, Inc. #liquidbiopsy #t #nextgenerationsequencing #genetiktan #cancer #caninecancer #oncok #theliquidbiopsycompanyforpets #theliquidbiopsytestfordogs #dogsofinstagram #veterinariansofinstagram #vetsofinstagram #vetclinic #petdx #cancertest #genomics #bloodtest #cancerscreening #cancerdetectiondogs #cancerdetection #vetoncology #biotechnology #veterinaryscience #vetscience #vetmed #biotech #veterinarymedicine #moleculardiagnostics #caninehealth #likitbiyopsi

Thank you to our Session I - Innovations in CE speakers Xiaoxi Zhang, Thermo Fisher Scientific and Frédéric Ginot, ADELIS Technologies for presenting and thank you to our session chairs Mark Lies, Advanced Electrophoresis Solutions Ltd. (AES) and David A. Michels, Genentech, a Member of the Roche Group for planning this session. #casss #CEPharm2024 #CapillaryElectrophoresis #biopharmaceuticals

Retour en vidéo sur la présentation du Professeur Sébastien Salas à l’ESMO - European Society for Medical Oncology Explorez les nouvelles possibilités d’analyses scientifiques sur l’ADN libre circulant grâce à la technologie #BIABooster dans le cadre de l’étude SChISM dirigée par le Pr. Salas, oncologue à l’Hôpital de la Timone à Marseille. Retrouvez la vidéo ici : https://lnkd.in/eufJ7Ryh

Greetings to our esteemed Japanese partner KINRYO ELECTRIC for presenting our #ZETALIF Induced Fluorescence Detector at #JASIS2024. #Fluorescence #DNA

Discover our BIABooster Innovative Solution for DNA analysis in oncology, on our partner’s booth ID SOLUTIONS (Hall 3 – Booth #653). This multi-injection platform enables analysis of the size profile of cell-free DNA directly from plasma at very high sensitivity <5 fg/µL. #DNA #RNA #oncology #ESMO2024

We are pleased to inform that Prof. Sebastien Salas (AP-HM, Cancer Research Center of Marseille) will be presenting a poster on SChISM study at ESMO 2024 Barcelona. This clinical study using BIABooster innovative technology is aimed to assess the performance of the cfDNA size profile before treatment to early predict response and survival following immunotherapy for four cancer types, to early adapt therapeutic strategy and prevent ICI-related progression or toxicity. Come and discuss with him on : ”Long circulating-free DNA fragments predict early-progression (EP) and progression-free-survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): a new biomarker”. #cfDNA #Biomarker #immunotherapy

CE PHARM 2024: Join Frédéric Ginot on Monday 16th September for a presentation on practical implementations of DNA analysis by electro-hydrodynamic actuation, focusing on examples where no prior purification of DNA is required. View the abstract: https://lnkd.in/eUjbxruP https://lnkd.in/dNVAFrq2 #CEPharm2024 #Adelis #DNA #RNA

ASCO 2024: ADELIS participates in groundbreaking study predicting Immunotherapy resistance with cell-free DNA analysis Our findings highlight that cell-free DNA fragments can predict early progression in patients with advanced or metastatic cancer undergoing immune-checkpoint inhibition. Standard PD-L1 testing identifies 60% of newly diagnosed patients as eligible for immuno-oncology treatments. However, 20% of eligible patients are missed, and among those identified, 50% do not respond to treatment, with about 30% experiencing severe adverse effects. The SCHISM study, presented at ASCO 2024, is addressing this critical issue by analyzing circulating DNA fragments. Intermediate data from this groundbreaking study were showcased at the conference. A key factor in the project's success is the size profile analysis of circulating DNA, enabled by our BIABOOSTER technology. Read the full abstract online: https://vist.ly/3beyd #DNA #Oncology #Sequencing

Congratulations to Valérie Taly, Stéphanie Descroix, and Karla Perez-Toralla on the publication of "Microfluidics Diagnostics, Methods, and Protocols" in the esteemed Methods in Molecular Biology series. We are proud to have contributed to Chapter 2, which details the efficient measurement of circulating DNA size distribution using microfluidic chips and capillary electrophoresis instruments. Learn more: https://vist.ly/38ph8 #DNA #sequencing #biology